You are here
MANDALMED, INC.
UEI: NPGNAQVJ3VZ7
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Biologic Inhibitor of Galectin-3 for Liver Fibrosis
Amount: $299,900.00PROJECT SUMMARY ABSTRACT Chronic liver disease affects approximatelymillion people in the United States and leads to more thandeaths each yearThe overall goal of this project is to develop a protein b ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction Supplement
Amount: $2,001,205.00This Administrative Supplement is for AimCboldface fontthat is focused on testing efficacy of a protein inhibitor of galectinin an ischemia reperfusionI Rminiswine model of myocardial infarctionMIIn t ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction
Amount: $224,734.00PROJECT SUMMARY ABSTRACT The overall goal of this project is to develop a human protein that is an inhibitor of galectin as a biologic to aid in the prevention and treatment of harmful remodeling a ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction
Amount: $299,958.00DESCRIPTION (provided by applicant): The wound-healing response of the human body to injuries involves induction of fibrosis, which is a dynamic scarring process. When fibrosis occurs in internal orga ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Model of the Human Testis for Reproductive Toxicology
Amount: $250,000.00DESCRIPTION (provided by applicant): More than 87,000 chemicals have been developed and distributed over the past 50 years. The vast majority of these have not been tested for potential toxic effects ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Preclinical Testing of Galectin-3C for Multiple Myeloma
Amount: $363,936.00DESCRIPTION (provided by applicant): The overall goal is development of a novel human protein, Galectin-3C, as a treatment for multiple myeloma (MM) that can be given with other agents to increase the ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity
Amount: $255,200.00DESCRIPTION (provided by applicant): The overall goal of the Phase I research is to develop a three-dimensional model of the blood-testis barrier (BTB) consisting of primary human Sertoli cells cultur ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
NO-donor/SOD-mimetics for diabetic nephropathy
Amount: $382,084.00DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease ...
SBIRPhase II2007Department of Health and Human Services National Institutes of Health -
Novel SOD-mimetics for type 1 diabetes
Amount: $207,730.00DESCRIPTION (provided by applicant): Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing pancreatic p-cells. There is no effective drug therapy to prevent the development of ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
NO-donor/SOD-mimetics for diabetic nephropathy
Amount: $134,000.00DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health